XPH ETF News
NYSEARCA: XPHState Street Investment ManagementHealthETFUSD
64.65+1.02 (+1.60%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
XPH news summary
We found 2 recent headlines mentioning State Street SPDR S&P Pharmaceuticals (XPH): 2 in the past week and 2 in the past 30 days, most often from Nasdaq. For price context, XPH is up 1.60% at $64.65. The most recent story, "Better Pharma ETF: iShares IHE vs. State Street XPH", was published by Nasdaq on Oct 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest XPH headlines
- Better Pharma ETF: iShares IHE vs. State Street XPHKey PointsThe iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio.NasdaqIHE, XPH, STT
- Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting PharmaKey PointsThe VanEck Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF both carry an identical expense ratio of 0.35%.NasdaqXPH, BBH